MOH lists abrocitinib on the medical assistance fund

The drug is used to treat atopic dermatitis.

The Ministry of Health (MOH) will list abrocitinib on its Medication Assistance Fund (MAF) on 1 March 2024.

Pfizer's abrocitinib is an oral tablet used to treat moderate-to-severe atopic dermatitis (AD). Eligible patients can now access alternative treatment options from public healthcare institutions.

Abrocitinib has been studied in the JADE clinical program, which involved over 3,800 adults and adolescents with moderate-to-severe AD.

Patients who received abrocitinib reported rapid relief from chronic itch and significant improvements in skin clearance.

“The subsidization of newer therapeutics will now improve accessibility to treatments for AD patients who rely on alternative treatments to manage their symptoms,” Ursula Soh, founder of Eczema Support Group Singapore (ESGS) said.